Melbourne, Australia, May 08, 2026 (GLOBE NEWSWIRE) -- HIGHLIGHTS Amplia and ANZGOG enter into agreement to conduct a clinical study in ovarian cancer evaluating narmafotinib in combination with standard-of-care chemotherapyOvarian cancer represents a major target for FAK inhibition therapy based on typically higher levels of FAK expression and fibrous nature of tumourThe study to enrol patients with high-grade serous ovarian cancer (HGSOC) who have not responded to platinum-based chemotherapy prior to surg ...